FDA Appoints New Leader for Drug Program
WASHINGTON — The Food and Drug Administration (FDA) has appointed Dr. George Tidmarsh, a seasoned pharmaceutical executive, to lead its Center for Drug Evaluation and Research. This marks another significant leadership change at the agency.
Dr. Tidmarsh, known for his expertise in cancer and pediatrics, steps in to fill the position after Dr. Jacqueline Corrigan-Curay announced her retirement. As the head of the FDA’s drug program, he will oversee the safety and effectiveness of medications available in the United States.
His new role comes with challenges, including the impending review of the abortion pill mifepristone, as part of a broader initiative led by FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr. The FDA is also focusing on evaluating other familiar medications, such as antidepressants and hormone-replacement therapies.
Dr. Tidmarsh has a history of founding and leading several pharmaceutical companies, including Horizon Pharmaceuticals, which produces anti-inflammatory medication for arthritis. He has also served as an adjunct professor at Stanford University.
The FDA’s drug center is the agency’s largest division, employing nearly 6,000 people who are tasked with ensuring the safety and efficacy of both new and existing drugs. Despite its size and importance, the center has experienced significant staff reductions, with around 2,000 employees laid off under recent federal workforce cuts overseen by Kennedy. This trend has raised concerns about the agency’s ability to carry out timely drug reviews.
The drug center has been without a permanent director since January, when Dr. Patrizia Cavazzoni stepped down shortly before President Trump took office. The agency has seen a turnover in senior leadership due to retirements and resignations, significantly affecting its operations.
While such leadership changes are common, it’s noteworthy that FDA center directors usually maintain their roles for many years, providing stability across different administrations. In a surprising move earlier this year, Makary appointed Dr. Vinay Prasad, a vocal critic of the FDA’s COVID-19 response, to lead the vaccine center.
As the FDA continues to navigate these changes, all eyes will remain on Dr. Tidmarsh as he takes on the responsibility of overseeing crucial decisions that impact public health and the pharmaceutical landscape in America.
